A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

BMC Research Notes

Gerard F Notario⁷  Gregory A Schulz⁷  Anna I Kruglova²  Konstantin M Gudkov²  Andrey P Prodeus³  Leyla S Namazova-Вaranova⁶  Yurii V Lobzin⁸  Elena S Keshishyan⁴  Elena A Degtiareva⁵  Elena N Baibarina¹  Tatyana V Turti⁶ 

[1] Center for Obstetrics, Gynecology, and Perinatology, Moscow, Russia;Abbott, Moscow, Russia;Federal Scientific Clinical Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia;Moscow Science Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russia;Peoples’ Friendship University of Russia, Moscow, Russia;Scientific Center of Children’s Health, RAMS, Lomonosovskiy Prospect, 2/62, Moscow, 119991, Russia;Abbott, Abbott Park, IL, USA;Institute for Child Infections, St. Petersburg, Russia

关键词: Preterm infant;    Lower respiratory tract infection;    Immunoprophylaxis;    Congenital heart disease;    Bronchopulmonary dysplasia;   

Others  :  1165777
DOI  :  10.1186/1756-0500-5-484

 received in 2012-03-23, accepted in 2012-08-27,  发布年份 2012

【 摘 要 】

Background

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary illness, including congenital heart disease (CHD) and bronchopulmonary dysplasia (BPD). No vaccine is currently approved for the prevention of RSV infection. It is recommended that children at high risk be prophylactically administered palivizumab, a monoclonal antibody that has been shown in a number of clinical studies to reduce hospitalization rates due to serious RSV infection. The objective of the current study was to determine the safety and effectiveness of palivizumab in preventing serious RSV disease in high-risk children in the Russian Federation. Children at high risk of serious RSV disease (ie, born at ≤35 wk gestational age and ≤6 mo of age, and/or aged ≤24 mo with BPD or hemodynamically significant CHD) were enrolled. Subjects were to receive 3 to 5 monthly injections of palivizumab 15 mg/kg (depending on the month of the initial injection) over the RSV season. The primary endpoint was RSV-related hospitalizations. Adverse events (AEs) were reported through 100 days following the final injection.

Results

One hundred subjects received ≥1 injection of palivizumab; 94 completed their dosing schedule. There were no RSV hospitalizations or deaths. Six of 7 subjects hospitalized for respiratory/cardiac conditions had an RSV test, which was negative in all cases. Three non-serious AEs (acute intermittent rhinitis and rhinitis, 1 subject; atopic dermatitis, 1 subject) were considered possibly related to palivizumab. All other AEs were mild or moderate and considered not related/probably not related to palivizumab.

Conclusion

Palivizumab was generally well tolerated and effectively prevented serious RSV infection in a mixed population of high-risk children in the Russian Federation.

Trial registration

ClinicalTrials.gov: NCT01006629

【 授权许可】

   
2012 Turti et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, et al.: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375(9725):1545-1555.
• [2]Tatochenko V, Uchaikin V, Gorelov A, Gudkov K, Campbell A, Schulz G, Prahl R, Notario G: Epidemiology of respiratory syncytial virus in children
• [3]Oshansky CM, Zhang W, Moore E, Tripp RA: The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol 2009, 4(3):279-297.
• [4]Stollenwerk N, Harper RW, Sandrock CE: Bench-to-bedside review: rare and common viral infections in the intensive care unit–linking pathophysiology to clinical presentation. Crit Care 2008, 12(4):219. BioMed Central Full Text
• [5]Empey KM, Peebles RS Jr, Kolls JK: Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010, 50(9):1258-1267.
• [6]Tregoning JS, Schwarze J: Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 2010, 23(1):74-98.
• [7]Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN: New insights for development of a safe and protective RSV vaccine. Hum Vaccin 2010, 6(6):482-492.
• [8]Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O’Grady J, Koenig S, Tamura JK, et al.: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176(5):1215-1224.
• [9]The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102(3):531-537.
• [10]Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143(4):532-540.
• [11]Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB: Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol 2007, 42(3):189-192.
• [12]Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J: Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003, 22(9):823-827.
• [13]Mitchell I, Paes BA, Li A, Lanctot KL: CARESS: The Canadian Registry of Palivizumab. Pediatr Infect Dis J 2011, 30(8):651-655.
• [14]Romero JR: Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J 2003, 22(2 Suppl):S46-S54.
• [15]Singleton R, Dooley L, Bruden D, Raelson S, Butler JC: Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J 2003, 22(6):540-545.
• [16]Henckel E, Luthander J, Berggren E, Kapadia H, Naver L, Norman M, Bennet R, Eriksson M: Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Pediatr Infect Dis J 2004, 23(1):27-31.
• [17]Morris SK, Dzolganovski B, Beyene J, Sung L: A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis 2009, 9:106. BioMed Central Full Text
• [18]From the American Academy of Pediatrics: Policy statements–modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009, 124(6):1694-1701.
• [19]Langley GF, Anderson LJ: Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J 2011, 30(6):510-517.
• [20]Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O’Brien K, et al.: The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004, 23(9):806-814.
• [21]Weber MW, Milligan P, Hilton S, Lahai G, Whittle H, Mulholland EK, Greenwood BM: Risk factors for severe respiratory syncytial virus infection leading to hospital admission in children in the western region of The Gambia. Int J Epidemiol 1999, 28(1):157-162.
• [22]Shafey O, Eriksen M, Ross H, Mackay J: The Tobacco Atlas. 3rd edition. American Cancer Society; Available at: www.tobaccoatlas.org webcite. Accessed May 12, 2011
• [23]Gannon JC: Global infectious disease threat and its implications for the United States. National Intelligence Council, Washington, DC; 2000.
• [24]WHO Health Status Statistics: Mortality Available at: http://www.who.int/healthinfo/statistics/indneonatalmortality/en/ webcite Accessed May 12, 2011
• [25]Wuhib T, McCarthy BJ, Chorba TL, Sinitsina TA, Ivasiv IV, McNabb SJ: Underestimation of infant mortality rates in one republic of the former Soviet Union. Pediatrics 2003, 111(5 Pt 1):e596-e600.